Skip to main content

Table 2 Duration of meropenem and concomitant antimicrobial therapy

From: Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial

 Standard-dose meropenem (n = 38)High-dose meropenem (n = 38)P value
Day of meropenem therapy, median (IQR)6 (3–16)5 (3–21)0.035*
Concomitant antimicrobial therapy, n (%)16 (42.1)19 (50)0.646
 Colistin, n (%)3 (18.8)2 (10.5)0.642
 Vancomycin, n (%)7 (43.8)6 (31.6)0.503
 Cotrimoxazole, n (%)1 (6.3)4 (21.1)0.347
 Levofloxacin, n (%)0 (0)3 (15.8)0.234
 Amikacin, n (%)4 (25)3 (15.8)0.677
 Azithromycin, n (%)1 (6.3)2 (10.5)1.000
 Oseltamivir, n (%)2 (12.5)2 (10.5)1.000
De-escalation, n (%)21 (55.3)25 (65.8)0.436
  1. *Statistically significant difference